2024-03-28T08:45:39Zhttp://repisalud.isciii.es/oai/requestoai:repisalud.isciii.es:20.500.12105/142392022-07-15T12:52:57Zcom_20.500.12105_2060com_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_2061
00925njm 22002777a 4500
dc
Hildebrandt, Anke
author
Zintl, Annetta
author
Montero-Clemente, Estrella
author
Hunfeld, Klaus-Peter
author
Gray, Jeremy
author
2021-09-09
Babesiosis is attracting increasing attention as a worldwide emerging zoonosis. The first case of human babesiosis in Europe was described in the late 1950s and since then more than 60 cases have been reported in Europe. While the disease is relatively rare in Europe, it is significant because the majority of cases present as life-threatening fulminant infections, mainly in immunocompromised patients. Although appearing clinically similar to human babesiosis elsewhere, particularly in the USA, most European forms of the disease are distinct entities, especially concerning epidemiology, human susceptibility to infection and clinical management. This paper describes the history of the disease and reviews all published cases that have occurred in Europe with regard to the identity and genetic characteristics of the etiological agents, pathogenesis, aspects of epidemiology including the eco-epidemiology of the vectors, the clinical courses of infection, diagnostic tools and clinical management and treatment.
Pathogens. 2021;10(9):1165.
2076-0817
http://hdl.handle.net/20.500.12105/14239
34578196
10.3390/pathogens10091165
Pathogens (Basel, Switzerland)
Babesia divergens
Babesia microti
Babesia venatorum
European babesiosis
Ixodes ricinus
Clinical cases
Diagnosis
Epidemiology
Parasite identity
Treatment
Human Babesiosis in Europe